BONORA, Stefano
 Distribuzione geografica
Continente #
NA - Nord America 18.243
EU - Europa 11.856
AS - Asia 4.703
SA - Sud America 314
AF - Africa 258
OC - Oceania 73
Continente sconosciuto - Info sul continente non disponibili 25
Totale 35.472
Nazione #
US - Stati Uniti d'America 17.942
CN - Cina 2.954
IT - Italia 2.048
DK - Danimarca 1.823
IE - Irlanda 1.297
DE - Germania 1.188
SE - Svezia 1.063
FR - Francia 1.001
UA - Ucraina 720
FI - Finlandia 702
GB - Regno Unito 577
KR - Corea 514
AT - Austria 353
PL - Polonia 299
VN - Vietnam 254
IN - India 228
CA - Canada 205
NL - Olanda 184
ES - Italia 168
SG - Singapore 154
BR - Brasile 145
JP - Giappone 125
ZA - Sudafrica 110
ID - Indonesia 86
RO - Romania 81
TW - Taiwan 78
BE - Belgio 75
MX - Messico 74
TH - Thailandia 68
RU - Federazione Russa 65
AU - Australia 63
CH - Svizzera 60
AR - Argentina 51
HK - Hong Kong 46
TR - Turchia 46
CO - Colombia 43
PK - Pakistan 31
CL - Cile 30
GR - Grecia 29
PE - Perù 29
PT - Portogallo 27
EU - Europa 22
IL - Israele 20
IR - Iran 20
UZ - Uzbekistan 19
NG - Nigeria 17
KE - Kenya 16
UG - Uganda 16
HR - Croazia 15
PH - Filippine 15
SN - Senegal 14
CZ - Repubblica Ceca 12
EG - Egitto 12
ET - Etiopia 12
BG - Bulgaria 11
SK - Slovacchia (Repubblica Slovacca) 11
NZ - Nuova Zelanda 10
NO - Norvegia 9
SA - Arabia Saudita 8
TZ - Tanzania 8
EC - Ecuador 7
MU - Mauritius 7
MY - Malesia 7
HU - Ungheria 6
LV - Lettonia 6
MW - Malawi 6
SD - Sudan 6
TN - Tunisia 6
AE - Emirati Arabi Uniti 5
RS - Serbia 5
CR - Costa Rica 4
CU - Cuba 4
DZ - Algeria 4
JO - Giordania 4
MZ - Mozambico 4
BO - Bolivia 3
BY - Bielorussia 3
CD - Congo 3
CM - Camerun 3
DO - Repubblica Dominicana 3
EE - Estonia 3
GT - Guatemala 3
KZ - Kazakistan 3
LU - Lussemburgo 3
MD - Moldavia 3
PA - Panama 3
PR - Porto Rico 3
VE - Venezuela 3
AP - ???statistics.table.value.countryCode.AP??? 2
BJ - Benin 2
BT - Bhutan 2
GA - Gabon 2
GH - Ghana 2
IQ - Iraq 2
LI - Liechtenstein 2
LK - Sri Lanka 2
LT - Lituania 2
MO - Macao, regione amministrativa speciale della Cina 2
NA - Namibia 2
NP - Nepal 2
Totale 35.447
Città #
Ann Arbor 3.773
Beijing 2.198
Chandler 1.952
Dublin 1.292
Houston 1.188
Fairfield 881
Ashburn 659
Villeurbanne 622
Wilmington 601
Torino 554
Jacksonville 529
Dearborn 479
Medford 467
Princeton 441
Woodbridge 431
Redwood City 384
Seattle 347
Nyköping 314
Vienna 298
Warsaw 285
Cambridge 268
Pisa 185
Milan 184
Boston 140
New York 134
Fremont 130
Dong Ket 116
Turin 115
Boardman 112
Singapore 93
Guangzhou 82
Toronto 79
Verona 75
Shanghai 68
San Diego 64
Nanjing 62
Paris 57
Hangzhou 54
Norwalk 52
Brussels 51
Taipei 51
Hefei 49
Rome 49
Kunming 48
São Paulo 43
Helsinki 40
Munich 40
Los Angeles 38
Nürnberg 38
Washington 38
Chicago 36
Falls Church 35
Pune 33
Jakarta 31
Ottawa 31
Cape Town 30
Jinan 30
Phoenix 30
Buenos Aires 28
Chengdu 28
Seoul 28
Mountain View 27
London 26
Santiago 26
Silver Spring 26
Lachine 23
Lima 22
Omaha 22
Arlington 21
Bengaluru 21
Buffalo 21
Dallas 21
Hebei 21
Tokyo 21
Hanoi 20
Changsha 19
Montreal 19
Upper Marlboro 19
Des Moines 18
Tariceni 18
Toulouse 18
Amsterdam 17
Barcelona 17
Hong Kong 17
Zhengzhou 17
Atlanta 16
Copenhagen 16
Duncan 16
Frankfurt am Main 16
Mumbai 16
Shenyang 16
Wuhan 16
Leawood 15
Nanchang 15
Piemonte 15
Baltimore 14
Edinburgh 14
Fuzhou 14
Istanbul 14
Kharkiv 14
Totale 21.314
Nome #
Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization? 770
Pharmacokinetics and pharmacodynamics of antiretrovirals in the central nervous system. 691
Cytomegalovirus central nervous system compartmentalization in a patient presenting with AIDS 581
Cardiac dysfunction in pauci symptomatic human immunodeficiency virus patients: a meta-analysis in the highly active antiretroviral therapy era 465
Antiretroviral therapy in geriatric HIV patients: The GEPPO cohort study 396
The outcome of HIV-positive late presenters according to detectable CMV DNA and anti-CMV treatment 392
High prevalence at computed coronary tomography of non-calcified plaques in asymptomatic HIV patients treated with HAART: A meta-analysis 364
Cerebrospinal Fluid Inhibitory Quotients of Antiretroviral Drugs in HIV-positive Patients are Associated with Compartmental Viral Control. 356
Elvitegravir/Cobicistat/Tenofovir/Emtricitabine Penetration in the Cerebrospinal Fluid of Three HIV-Positive Patients 339
High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis. 307
Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms. 299
Prevalence and predictors of long corrected QT interval in HIV-positive patients: a multicenter study 298
Heart failure in patients with human immunodeficiency virus: a review of the literature. 292
A UPLC-MS-MS method for the simultaneous quantification of first-line antituberculars in plasma and in PBMCs 291
HIV-1 Very Low Level Viremia is Associated with Virological Failure in HAART-treated Patients 280
Tenofovir coadministration is not associated with lower unboosted atazanavir plasma exposure in the clinical setting 277
Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment. 275
Tenofovir clearance is reduced in hiv-positive patients with subclinical tubular impairment 264
Raltegravir penetration in seminal plasma of healthy volunteers. 247
Evaluation of the mean corpuscular volume of peripheral blood mononuclear cells of HIV patients by a coulter counter to determine intracellular drug concentrations. 247
CNS-Targeted Antiretroviral Strategies: When Are They Needed and What to Choose 242
Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells. 235
Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study) 234
Are intracellular drug concentrations underestimated? The role of medium corpuscular volume (MCV) for a correct determination 228
Single-nucleotide polymorphisms ABCB1 3435C>T, 1236C>T and CYP2B6 516G>T influence plasma concentrations of Efavirenz (EFV). 227
A pilot study on the efficacy, pharmacokinetics and safety of atazanavir in patients with end-stage liver disease 226
Presence of EBV DNA in Cerebrospinal Fluid is Associated with Greater HIV RNA and Inflammation 212
Lower dolutegravir plasma concentrations in HIV-positive patients receiving valproic acid 207
SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV 202
Extra Corporeal Membrane Oxygenation (ECMO) in three HIV-positive patients with acute respiratory distress syndrome 201
Pharmacogenetics of Antiretrovirals' Penetrations into Cerebrospinal Fluid 200
Descrittiva della farmacocinetica (PK) e della farmacogenetica (PG) dell'Efavirenz in una coorte di popolazione italiana 196
Prevalence and predictors of blood-brain barrier damage in the HAART era. 195
Acute HIV infection: Improved algorithms for HIV testing. 194
SLC28A2 65C>T predict Sustained Virological Response in patients with hepatitis C treated with interferon and ribavirin, considering all HCV genotype and genotype 1/4. 192
Cerebrospinal fluid viral load and neopterin in HIV-positive patients with undetectable viraemia 179
Pharmacogenetic determinants of kidney-associated urinary and serum abnormalities in antiretroviral-treated HIV-positive patients 176
Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens 174
Elimination half-life may explain the relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1. 174
Could ritonavir intracellular concentrations have a role as active drugs when used as a booster PIs? 172
Cardiovascular disease in HIV patients: from bench to bedside and backwards 172
An HPLC-PDA Method for the Simultaneous Quantification of the HIV Integrase Inhibitor Raltegravir, the New Nonnucleoside Reverse Transcriptase Inhibitor Etravirine, and 11 Other Antiretroviral Agents in the Plasma of HIV-Infected Patients 171
SLC29A1 −706G>C predict haemoglobin decrease in patients with hepatitis C treated with interferon and ribavirin 171
West African Immigrants and New Patterns of Malaria Imported to North Eastern Italy. 169
Effect of Darunavir (DRV) genotypic inhibitory quotient (gIQ) on the virological response to DRV-containing salvage regimens at 24 weeks 168
Failure of prophylaxis against PCP in patients with HIV infection. 166
Clinical pharmacology of tenofovir clearance: a pharmacokinetic/pharmacogenetic study on plasma and urines 162
A population pharmacokinetic model confirms an association between a pregnane-X-receptor (PXR) polymorphism and unboosted atazanavir clearance 160
Etravirine Plasma Exposure is Associated with Virological Efficacy in Treatment-experienced HIV-positive Patients. 160
TENOFOVIR AND EMTRICITABINE CSF-TO-PLASMA RATIOS CORRELATE TO THE EXTENT OF BLOOD BRAIN-BARRIER DAMAGE 160
Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice daily) dual regimen in the clinical setting 158
Analysis of determinants of long-term efficacy of unboosted atazanavir-based regimens in the clinical setting 155
In-hospital and long-term outcomes of HIV-positive patients undergoing PCI according to kind of stent: a meta-analysis 155
Pharmacokinetics of 400 mg of raltegravir once daily in combination with atazanavir/ritonavir plus two nucleoside/nucleotide reverse transcriptase inhibitors. 154
An improved HPLC fluorimetric method for the determination of enfuvirtide plasma levels in HIV-infected patients 153
Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics. 153
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update December 2014 152
INTRACELLULAR ACCUMULATION OF RITONAVIR ASSOCIATED WITH DIFFERENT BOOSTED PIS 152
Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to pegylated interferon/ribavirin treatment in patients infected with hepatitis C virus genotype 1/4. 151
Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection. 151
A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation. 150
Role of therapeutic drug monitoring in a patient with human immunodeficiency virus infection and end-stage liver disease undergoing orthotopic liver transplantation 150
A pilot study evaluating plasma and intracellular pharmacokinetics (PK) of switching from atazanavir (ATV) 400mg QD to ATV 200 mg BID in HIV+ patients. 149
Tenofovir and emtricitabine cerebrospinal fluid-to-plasma ratios correlate to the extent of blood-brainbarrier damage. 148
A validated high-performance liquid chromatography-ultraviolet method for quantification of the CCR5 inhibitor maraviroc in plasma of HIV-infected patients. 148
Pharmacokinetics and hepatotoxicity of lopinavir/ritonavir in non-cirrhotic HIV and hepatitis C virus (HCV) co-infected patients 147
A filter-based cross-sectional analysis of an HIV-positive, HAART-treated cohort in rural Burundi: pharmacokinetics, pharmacogenetics and viral load 147
Determinants of Tenofovir Plasma Trough Concentrations: a Cross-sectional Analysis in the Clinical Setting 147
Clinical pharmacology of complex regiment of antiretroviral therapy including Etravirine, Maraviroc and Raltégravir. 146
Tenofovir Plasma Concentrations According to Companion Drugs: a Cross-sectional Study in HIV-positive Patients with Normal Renal Function. 145
Single-nucleotide polymorphism PXR 7635G>A influences plasma concentrations of Efavirenz in CYP2B6 516G>T carriers 145
What do we know about tailoring treatment with tenofovir? 144
Detectable cerebrospinal fluid JCV DNA in late-presenting HIV-positive patients: beyond progressive multifocal leukoencephalopathy? 144
Undetectable Ritonavir Plasma Concentrations in Different Boosted PI-based Regimens as a Marker of Non-Adherence: analysis of a large TDM Registry 143
Pharmacokinetic Determinants of Immunovirological Response in HIV Very Late Presenters 142
Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients. 142
HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients 141
Pharmacokinetic and pharmacodynamic determinants of early virological response to enfuvirtide-based regimens in HIV-positive patients 140
Efficacy, Safety and Pharmacokinetics of Atazanavir (200 mg twice-daily) plus Raltegravir (400 mg twice-daily) Dual Regimen in the Clinical Setting 140
Pharmacokinetics of Raltegravir, Etravirine and Maraviroc regimen in the clinical setting 140
Viral rebound after switch to Maraviroc-Raltegravir dual therapy 139
MONITORING OF VIROLOGICAL AND PHARMACOLOGICAL CEREBROSPINAL FLUID PARAMETERS IN HAART-TREATED HIV-POSITIVE PATIENTS IN THE CLINICAL SETTING 139
Clinically significant drug interaction between tipranavir-ritonavir and phenobarbital in an HIV-infected subject 138
Intracellular accumulation of the new integrase inhibitors elvitegravir and dolutegravir in HIV patients 137
Continuous intravenous infusion of enfuvirtide in an out-clinic patient with a multi resistent HIV strain and severe injection-site reactions 137
Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens. 137
SLCO3A1 expression is a major determinant of atazanavir PBMC penetration in HIV infected patients 136
Pharmacokinetics of the Dual NRTI- and Protease Inhibitor-sparing Regimen Raltegravir plus Nevirapine in HIV-1+ Patients 136
Steady-state Raltegravir Penetration in Seminal Plasma of Healthy Volunteers 135
GREATER IMMUNOLOGICAL RECOVERY ASSOCIATED WITH ADDITIONAL ENFUVIRTIDE IN THE TREATMENT OF NAIVE HIV-INFECTED PATIENTS AT VERY ADVANCED DISEASE STAGES: 24-WEEK RESULTS OF A RANDOMIZED, CONTROLLED, PILOT STUDY 135
Short-term additional enfuvirtide therapy is associated with a greater immunological recovery in HIV very late presenters: a controlled pilot study. 133
High Interpatient Variability of Raltegravir Cerebrospinal Fluid Concentrations in HIV-positive Patients: a Pharmacogenetic Analysis 133
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? 133
Role of vitamin D pathway gene polymorphisms on rifampicin plasma and intracellular pharmacokinetics 131
Pharmacokinetics (PK) of the co-administration of raltegravir (RAL) and amlodipine (AML) to male and female healthy volunteers 130
High incidence of infections in HIV-positive patients treated for lymphoproliferative disorders 130
Pharmacokinetics (PKS) of rifabutin (RIF) coadministered with lopinavir/ritonavir (LPV/r) in HIV patients affected by tuberculosis (TB) 129
Comparative safety and efficacy of statins for primary prevention in human immunodeficiency virus-positive patients: a systematic review and meta-analysis 128
Dual antiretroviral therapies are effective and safe regimens in the central nervous system of neurologically symptomatic people living with HIV 128
Is Maraviroc a substrate for SLCO1B1? 127
Totale 20.259
Categoria #
all - tutte 88.733
article - articoli 0
book - libri 0
conference - conferenze 17.729
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 106.462


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019984 0 0 0 0 0 0 0 0 0 0 657 327
2019/20206.910 218 214 267 607 787 1.419 649 358 411 575 658 747
2020/20214.466 615 197 249 246 404 359 323 159 447 371 316 780
2021/20226.295 540 453 545 604 429 439 562 512 352 256 714 889
2022/20236.212 631 368 123 579 651 1.584 462 455 676 122 330 231
2023/20242.407 355 457 158 159 240 402 78 180 55 119 204 0
Totale 37.139